Harnessing Minimal Residual Disease as a Predictor for Colorectal Cancer: Promising Horizons Amidst Challenges

Minimal Residual Disease (MRD) detection has emerged as an independent factor in clinical and pathological cancer assessment offering a highly effective method for predicting recurrence in colorectal cancer (CRC). The ongoing research initiatives such as the DYNAMIC and CIRCULATE-Japan studies, have...

Full description

Saved in:
Bibliographic Details
Published in:Medicina (Kaunas, Lithuania) Vol. 59; no. 10; p. 1886
Main Authors: Wen, Xiaofen, Coradduzza, Donatella, Shen, Jiaxin, Scanu, Antonio Mario, Muroni, Maria Rosaria, Massidda, Matteo, Rallo, Vincenzo, Carru, Ciriaco, Angius, Andrea, De Miglio, Maria Rosaria
Format: Journal Article
Language:English
Published: Switzerland MDPI AG 01.10.2023
MDPI
Subjects:
Biomarkers, Tumor - genetics
Biopsy
Cancer
Cancer therapies
Care and treatment
Chemotherapy
Clinical medicine
Clinical Relevance
Colorectal cancer
colorectal cancer (CRC)
Colorectal Neoplasms - diagnosis
Colorectal Neoplasms - genetics
Development and progression
Diagnosis
Disease
Humans
Japan
Metastasis
Minimal Residual Disease (MRD)
MRD clinical application in CRC
MRD techniques
Neoplasm, Residual - diagnosis
Oncology
Oncology, Experimental
Patients
Review
Serology
Tumors
Japan
colorectal cancer (CRC)
Minimal Residual Disease (MRD)
MRD techniques
MRD clinical application in CRC
ISSN:1648-9144, 1010-660X, 1648-9144
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Minimal Residual Disease (MRD) detection has emerged as an independent factor in clinical and pathological cancer assessment offering a highly effective method for predicting recurrence in colorectal cancer (CRC). The ongoing research initiatives such as the DYNAMIC and CIRCULATE-Japan studies, have revealed the potential of MRD detection based on circulating tumor DNA (ctDNA) to revolutionize management for CRC patients. MRD detection represents an opportunity for risk stratification, treatment guidance, and early relapse monitoring. Here we overviewed the evolving landscape of MRD technology and its promising applications through the most up-to-date research and reviews, underscoring the transformative potential of this approach. Our primary focus is to provide a point-to-point perspective and address key challenges relating to the adoption of ctDNA-based MRD detection in the clinical setting. By identifying critical areas of interest and hurdles surrounding clinical significance, detection criteria, and potential applications of basic research, this article offers insights into the advancements needed to evaluate the role of ctDNA in CRC MRD detection, contributing to favorable clinical options and improved outcomes in the management of CRC.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
ObjectType-Review-3
content type line 23
These authors contributed equally to this work.
ISSN:1648-9144
1010-660X
1648-9144
DOI:10.3390/medicina59101886